Home MarketAlembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd. Stock Info: As on 2017-11-24 15:55:31

Nse

515.50

1.20(0.23%)
Change%
52 Week Range
469.85
15.00
673.70
30.00
Open512.20
Day's Range411.44 - 617.16
Value Traded (in ₹ Cr.) 0.69

Bse

513.90

-0.45(-0.09%)
Change %
52 Week Range
469.75
20.00
709.30
23.00
Open517.35
Day's Range411.48 - 617.22
Value Traded (in ₹ Cr.) 0.11

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 137,007,545.00 72.68%
Mutual Funds/UTI 6,436,746.00 3.41%
FII 19,619,263.00 10.41%
Employee 0.00 0.00%
Public 20,710,408.00 10.99%
Government 0.00 0.00%
Others 4,134,563.00 2.19%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 3.78
Basic EPS (Rs.) 37.03
Cash EPS 40.85
BVPerShare Excl 81.17
Operating Revenue 158.70
PBDITPerShare 52.38
Dividend 0.00
NPPerShare 37.03
Current Ratio 2.31
Quick Ratio 1.37
PriceToBV 7.40
Earnings 0.06
PBDIT Margin 33.00
PBT Margin 30.52
NP Margin 23.33
Return On Assets 31.89
Retention Ratios 0.00
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,997.26
Total Expenses 2,083.95
EBITDA 987.54
PBT 913.31
PAT 698.14
Net Income 698.14
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,491.44
Total Expenses 997.94
EBITDA 447.78
PBT 492.02
PAT 369.15
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 37.70
Net worth 1,530.28
Investments 37.46
Total Liability 2,189.11
Total debt 0.00
Net block 789.59
Total Assets 2,189.11
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 37.70
Net worth 1,530.28
Investments 37.46
Total Liability 2,189.11
Total debt 0.00
Net block 789.59
Total Assets 2,189.11
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

535.05 535.15 -0.02
525.05537

Abbott India Ltd.

4977.5 4858.7 2.45
4810.055049

Ajanta Pharma Ltd.

1329.2 1327.15 0.15
12301362.3

Albert David Ltd.

361.2 323.55 11.64
285.5328

Alembic Ltd.

39.35 39.25 0.25
3940.45

Alkem Laboratories Ltd.

1987.9 1974.45 0.68
19442013.85

Alpa Laboratories Ltd.

32.35 32.3 0.15
30.333.5
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

56.5 53.35 5.9
44.0558.4

Aarti Drugs Ltd.

532.1 532 0.02
513.4537

Aayush Food & Herbs Ltd.

47.7 47.9 -0.42
40.152.7

Abbott India Ltd.

4968.65 4861.15 2.21
48505085

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 847.53
Cash from investing activities -293.07
Cash from financing activities -274.05
Net change in cash 280.41

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
ICICI Prudential Long Term Equity Fund 1.78%
ICICI Prudential Multicap Fund 1.84%
ICICI Prudential Balanced Fund 0.14%
DSP BlackRock Small And Mid Cap Fund 0.47%
SBI Pharma Fund 1.79%
ICICI Prudential Child Care Plan - Gift Plan 3.64%

Cadila bags approval for Minocycline Hydrochloride tablets

Cadila Healthcare Ltd has said that its arm Zydus Pharmaceuticals (USA) Inc. has received the final approval from the USFDA to market Minocycline Hydrochloride Extended - Release Tablets in strengths of 45 mg, 80 mg, 90 mg and 105 mg and 135 mg. Zydus also received the tentative approval for Minocycline Hydrochloride Extended - Release Tablets, 55 mg, 65 mg and 115 mg. “Minocycline Hydrochloride Extended - Release Tablets are a tetracycline-class drug, indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. It will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad,” the company said in a filing to the Bombay Stock Exchange. The group now has more than 170 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04. Meanwhile, shares of the company were trading at Rs 446.35 apiece, up 0.64 per cent from the previous close at 11:05 hrs on BSE.

24-11-2017 11:01

Revathi Equipment Ltd posts Q2 net profit of Rs 0.27 cr

The company reported standalone net profit during the quarter stood at Rs 0.27 crore compared to net loss of Rs 1.00 crore in the previous year quarter. Net revenue of the company declined by 0.46 per cent at Rs 10.81 crore in July-September quarter of this fiscal as against Rs 10.86 crore in the corresponding period last year. During July-September quarter, operating expenses dropped by 8.47 per cent to Rs 9.72 crore from Rs 10.62 crore in year ago period. Other Income dipped by 4.76 per cent at Rs 0.40 crore versus (Sep'16 Rs 0.42 crore). Operating Profit surged by 354.17 per cent to Rs 1.09 crore as against Rs 0.24 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 348.89 per cent in September quarter. Interest declined by 58.05 per cent y-o-y to Rs 0.73 crore, while Taxation increased by 257.14 per cent at Rs 0.33 crore (Sep'16 Rs -0.21 crore).

24-11-2017 10:27

Salasar Techno Q2 net profit jumps 41.61% at Rs 4.05 cr

The company reported standalone net profit of Rs 4.05 crore for the quarter ended September 30, 2017 as compared to Rs 2.86 crore in the same period last year, registering a year-on-year growth of 41.61 per cent. Net revenue of the company rose substantially by 31.30 per cent at Rs 95.22 crore in July-September quarter of this fiscal as against Rs 72.52 crore in the corresponding period last year. During July-September quarter, operating expenses increased by 32.08 per cent to Rs 89.42 crore from Rs 67.70 crore in year ago period. Other Income grew by 20.00 per cent at Rs 0.06 crore versus (Sep'16 Rs 0.05 crore). Operating Profit surged by 20.12 per cent to Rs 5.79 crore as against Rs 4.82 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 8.28 per cent in September quarter. Interest grew by 16.13 per cent y-o-y to Rs 0.36 crore, while Taxation decreased by 29.17 per cent at Rs 1.53 crore (Sep'16 Rs 2.16 crore).

24-11-2017 10:27

Sunil Healthcare Q2 net profit down 53.80% at Rs 0.79 cr

The company reported standalone net profit of Rs 0.79 crore for the quarter ended September 30, 2017 as compared to Rs 1.71 crore in the same period last year, registering a year-on-year decline of 53.80 per cent. Net revenue of the company declined by 5.58 per cent at Rs 22.85 crore in July-September quarter of this fiscal as against Rs 24.20 crore in the corresponding period last year. During July-September quarter, operating expenses dropped by 1.65 per cent to Rs 19.70 crore from Rs 20.03 crore in year ago period. Other Income grew by 11.76 per cent at Rs 0.19 crore versus (Sep'16 Rs 0.17 crore). Operating Profit slipped by 27.08 per cent to Rs 3.15 crore as against Rs 4.32 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 22.86 per cent in September quarter. Interest grew by 0.99 per cent y-o-y to Rs 1.02 crore, while Taxation decreased by 49.28 per cent at Rs 0.35 crore (Sep'16 Rs 0.69 crore).

24-11-2017 10:27

RIL’s arm closes sale of assets to BKV Chelsea

Reliance Industries Limited has said that its arm Reliance Marcellus II, LLC a subsidiary of Reliance Holding USA, Inc. has closed recently announced sale of its interest in certain upstream assets; which were operated by Carrizo Oil & Gas, Inc to BKV Chelsea LLC, an affiliate of Kalnin Ventures. In a transaction announced on October 06, 2017, Reliance agreed to sell its entire working interest in these upstream assets to BKV Chelsea for purchase consideration of USD 126 million with an effective date of April 01, 2017. Additionally, under the definitive documents, a contingent amount of up to USD 11.25 million may be paid to Reliance between years 2018 to 2020 based on certain gas price thresholds being achieved. The transaction closed on November 21, 2017 and Reliance received the purchase consideration subject to usual and customary purchase price adjustments. Meanwhile, shares of the company were trading at Rs 954.95 apiece, up 1.04 per cent from the previous close at 10:05 hrs on BSE.

24-11-2017 10:00

Alembic Pharmaceutic - Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2017.

With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has approved the Unaudited Financial Results for the quarter and half year ended on 30th September, 2017.

We enclose herewith the following:

a) Consolidated Unaudited Financial Results for the quarter and half year ended on 30th September, 2017 and Consolidated Statement of Assets and Liabilities as at 30th September, 2017.
b) Standalone Unaudited Financial Results for the quarter and half year ended on 30th September, 2017 and Standalone Statement of Assets and Liabilities as at 30th September, 2017.
c) Limited Review Report by Statutory Auditors on Consolidated as well as on Standalone Unaudited Financial Results.
d) Press Release.
e) Investor Presentation.

The time of commencement of the Board Meeting was 10:30 a.m. and the time of conclusion was 12:15 p.m.

We request you to kindly take the same on record.

07-Nov-2017 07:16 PM

Alembic Pharma completes acquisition of Orit Laboratories

Alembic Pharmaceuticals has said that through its 100 percent owned subsidiary, Alembic Pharmaceuticals Inc., it has completed acquisition of West Caldwell, New Jersey USA based generic drug developer Orit Laboratories LLC along with real estate, owned by Okner Realty LLC. Commenting on the development, Pranav Amin, Managing Director of Alembic Pharmaceuticals said, “We Welcome Dr. Satish Patel, Founder and CEO of Orit, and his impressive team to the Alembic family.” He said Dr Patel has proven expertise in the US generic pharmaceuticals industry, which will help Alembic. “This acquisition expands our basket of product offerings to our customers, shows our commitment to be a long term player in the US generic industry, and will help us have a powerful R&D footprint in the US,” Amin added. Meanwhile, shares of the company were trading at Rs 512 apiece, up 1.57 per cent from the previous close at 10:07 hours on BSE.

01-Nov-2017 10:01 AM

Alembic Pharmaceutic - Press Release

Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 01, 2017, titled Acquisition of US based generic drug developer Orit Laboratories LLC .

01-Nov-2017 09:05 AM

Alembic Pharmaceutic - Press Release / Media Release

Acquisition of US based generic drug developer Orit Laboratories LLC

01-Nov-2017 09:04 AM

Alembic Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates

Alembic Pharmaceuticals Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

26-Oct-2017 02:42 PM

Alembic Pharmaceutic - Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2017.

With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has approved the Unaudited Financial Results for the quarter and half year ended on 30th September, 2017.

We enclose herewith the following:

a) Consolidated Unaudited Financial Results for the quarter and half year ended on 30th September, 2017 and Consolidated Statement of Assets and Liabilities as at 30th September, 2017.
b) Standalone Unaudited Financial Results for the quarter and half year ended on 30th September, 2017 and Standalone Statement of Assets and Liabilities as at 30th September, 2017.
c) Limited Review Report by Statutory Auditors on Consolidated as well as on Standalone Unaudited Financial Results.
d) Press Release.
e) Investor Presentation.

The time of commencement of the Board Meeting was 10:30 a.m. and the time of conclusion was 12:15 p.m.

We request you to kindly take the same on record.

07-Nov-2017 07:16 PM

Alembic Pharmaceutic - Press Release / Media Release

Acquisition of US based generic drug developer Orit Laboratories LLC

01-Nov-2017 09:04 AM

Alembic Pharmaceutic - Analyst / Investor Meet - Intimation

The exchange is hereby informed that the Company will hold Post Results Conference Call on 7th November, 2017 as per the enclosed details.

Kindly take the same on record.

26-Oct-2017 02:41 PM

Corporate Details

About Management

2011 Alembic Pharmaceuticals Limited ( the Resulting C ompany ) was originally incorporated on 16th June, 2010 in the name and style 'Alembic Pharma Limited', under the Companies Act, 1956 and had received the Certificate of Commencement of business on 1st July, 2010. The company changed its name from Alembic Pharma Limited to Alembic Pharmaceuticals Limited and the Registrar of Companies, Gujarat has approved the change of name and issued a fresh certificate of incorporation consequent upon change of name on 12th March, 2011. 2012 Alembic and Breckenridge Announce Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiqr). Alembic Pharmaceuticals Limited enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. 2013 -Alembic gets USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA. 2014 -"Alembic announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A.". 2015 -Alembic Pharmaceuticals Ltd. arm signs exclusive agreement with Novartis 2016 - Alembic Pharma inks JV agreement with Orbicular Pharma

Registered Office

Samardung Busty, Namthang,

,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.